Selected research
Industry Research
Human Albumin Injection Industry Research Report 2026
Market perspective
The global Human Albumin Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Albumin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Albumin Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Albumin Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Albumin Injection include Takeda, Nanyue Biopharmaceuticals, Grifols, Hualan Bio, Baxter, SK Plasma, Octapharma, Kedrion Biopharma, Inc. and Instituto Grifols, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Albumin Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Albumin Injection Market by Company
Takeda
Nanyue Biopharmaceuticals
Grifols
Hualan Bio
Baxter
SK Plasma
Octapharma
Kedrion Biopharma, Inc.
Instituto Grifols
Green Cross
GE HealthCare
CSL Behring
Biotest (UK) Ltd
Bio Products Laboratory
Human Albumin Injection Segment by Type
Blood Extraction
Recombine
Human Albumin Injection Segment by Application
Hospital
Clinic
Human Albumin Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Albumin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Albumin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Albumin Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Albumin Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Albumin Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Albumin Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Extraction
- Recombine
Applications
- Hospital
- Clinic
Companies covered
- Takeda
- Nanyue Biopharmaceuticals
- Grifols
- Hualan Bio
- Baxter
- SK Plasma
- Octapharma
- Kedrion Biopharma, Inc.
- Instituto Grifols
- Green Cross
- GE HealthCare
- CSL Behring
- Biotest (UK) Ltd
- Bio Products Laboratory
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Albumin Injection Market Size (2021-2032)
- 2.2.2 Global Human Albumin Injection Sales (2021-2032)
- 2.2.3 Global Human Albumin Injection Market Average Price (2021-2032)
- 2.3 Human Albumin Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Blood Extraction
- 2.3.3 Recombine
- 2.4 Human Albumin Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Albumin Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Albumin Injection Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Human Albumin Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Albumin Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Albumin Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Albumin Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Albumin Injection, Product Type & Application
- 3.8 Global Manufacturers of Human Albumin Injection, Established Date
- 3.9 Global Human Albumin Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Human Albumin Injection Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Nanyue Biopharmaceuticals
- 4.2.1 Nanyue Biopharmaceuticals Company Information
- 4.2.2 Nanyue Biopharmaceuticals Business Overview
- 4.2.3 Nanyue Biopharmaceuticals Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Nanyue Biopharmaceuticals Human Albumin Injection Product Portfolio
- 4.2.5 Nanyue Biopharmaceuticals Recent Developments
- 4.3 Grifols
- 4.3.1 Grifols Company Information
- 4.3.2 Grifols Business Overview
- 4.3.3 Grifols Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Grifols Human Albumin Injection Product Portfolio
- 4.3.5 Grifols Recent Developments
- 4.4 Hualan Bio
- 4.4.1 Hualan Bio Company Information
- 4.4.2 Hualan Bio Business Overview
- 4.4.3 Hualan Bio Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hualan Bio Human Albumin Injection Product Portfolio
- 4.4.5 Hualan Bio Recent Developments
- 4.5 Baxter
- 4.5.1 Baxter Company Information
- 4.5.2 Baxter Business Overview
- 4.5.3 Baxter Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Baxter Human Albumin Injection Product Portfolio
- 4.5.5 Baxter Recent Developments
- 4.6 SK Plasma
- 4.6.1 SK Plasma Company Information
- 4.6.2 SK Plasma Business Overview
- 4.6.3 SK Plasma Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SK Plasma Human Albumin Injection Product Portfolio
- 4.6.5 SK Plasma Recent Developments
- 4.7 Octapharma
- 4.7.1 Octapharma Company Information
- 4.7.2 Octapharma Business Overview
- 4.7.3 Octapharma Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Octapharma Human Albumin Injection Product Portfolio
- 4.7.5 Octapharma Recent Developments
- 4.8 Kedrion Biopharma, Inc.
- 4.8.1 Kedrion Biopharma, Inc. Company Information
- 4.8.2 Kedrion Biopharma, Inc. Business Overview
- 4.8.3 Kedrion Biopharma, Inc. Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kedrion Biopharma, Inc. Human Albumin Injection Product Portfolio
- 4.8.5 Kedrion Biopharma, Inc. Recent Developments
- 4.9 Instituto Grifols
- 4.9.1 Instituto Grifols Company Information
- 4.9.2 Instituto Grifols Business Overview
- 4.9.3 Instituto Grifols Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Instituto Grifols Human Albumin Injection Product Portfolio
- 4.9.5 Instituto Grifols Recent Developments
- 4.10 Green Cross
- 4.10.1 Green Cross Company Information
- 4.10.2 Green Cross Business Overview
- 4.10.3 Green Cross Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Green Cross Human Albumin Injection Product Portfolio
- 4.10.5 Green Cross Recent Developments
- 4.11 GE HealthCare
- 4.11.1 GE HealthCare Company Information
- 4.11.2 GE HealthCare Business Overview
- 4.11.3 GE HealthCare Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GE HealthCare Human Albumin Injection Product Portfolio
- 4.11.5 GE HealthCare Recent Developments
- 4.12 CSL Behring
- 4.12.1 CSL Behring Company Information
- 4.12.2 CSL Behring Business Overview
- 4.12.3 CSL Behring Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CSL Behring Human Albumin Injection Product Portfolio
- 4.12.5 CSL Behring Recent Developments
- 4.13 Biotest (UK) Ltd
- 4.13.1 Biotest (UK) Ltd Company Information
- 4.13.2 Biotest (UK) Ltd Business Overview
- 4.13.3 Biotest (UK) Ltd Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biotest (UK) Ltd Human Albumin Injection Product Portfolio
- 4.13.5 Biotest (UK) Ltd Recent Developments
- 4.14 Bio Products Laboratory
- 4.14.1 Bio Products Laboratory Company Information
- 4.14.2 Bio Products Laboratory Business Overview
- 4.14.3 Bio Products Laboratory Human Albumin Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bio Products Laboratory Human Albumin Injection Product Portfolio
- 4.14.5 Bio Products Laboratory Recent Developments
5 Global Human Albumin Injection Market Scenario by Region
- 5.1 Global Human Albumin Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Albumin Injection Sales by Region: 2021-2032
- 5.2.1 Global Human Albumin Injection Sales by Region: 2021-2026
- 5.2.2 Global Human Albumin Injection Sales by Region: 2027-2032
- 5.3 Global Human Albumin Injection Revenue by Region: 2021-2032
- 5.3.1 Global Human Albumin Injection Revenue by Region: 2021-2026
- 5.3.2 Global Human Albumin Injection Revenue by Region: 2027-2032
- 5.4 North America Human Albumin Injection Market Facts & Figures by Country
- 5.4.1 North America Human Albumin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Albumin Injection Sales by Country (2021-2032)
- 5.4.3 North America Human Albumin Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Albumin Injection Market Facts & Figures by Country
- 5.5.1 Europe Human Albumin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Albumin Injection Sales by Country (2021-2032)
- 5.5.3 Europe Human Albumin Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Albumin Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Albumin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Albumin Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Albumin Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Albumin Injection Market Facts & Figures by Country
- 5.7.1 South America Human Albumin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Albumin Injection Sales by Country (2021-2032)
- 5.7.3 South America Human Albumin Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Albumin Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Albumin Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Albumin Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Albumin Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Albumin Injection Sales by Type (2021-2032)
- 6.1.1 Global Human Albumin Injection Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Human Albumin Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Human Albumin Injection Revenue by Type (2021-2032)
- 6.2.1 Global Human Albumin Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Albumin Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Albumin Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Albumin Injection Sales by Application (2021-2032)
- 7.1.1 Global Human Albumin Injection Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Human Albumin Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Human Albumin Injection Revenue by Application (2021-2032)
- 7.2.1 Global Human Albumin Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Albumin Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Albumin Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Albumin Injection Value Chain Analysis
- 8.1.1 Human Albumin Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Albumin Injection Production Mode & Process
- 8.2 Human Albumin Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Albumin Injection Distributors
- 8.2.3 Human Albumin Injection Customers
9 Global Human Albumin Injection Analyzing Market Dynamics
- 9.1 Human Albumin Injection Industry Trends
- 9.2 Human Albumin Injection Industry Drivers
- 9.3 Human Albumin Injection Industry Opportunities and Challenges
- 9.4 Human Albumin Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst